Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Reporting Period: Single event date (June 2, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing discloses a material corporate event regarding its IntelligentFingerprinting Drug Screening System.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulation FD Disclosure (Item 7.01):
- The Company announced the initiation of a multi-site Method Comparison Study.
- The study is designed to support an FDA 510(k) submission.
- The submission seeks U.S. market clearance for the IntelligentFingerprinting Drug Screening System specifically for the opiate codeine.
Guidance, Outlook, and Risks
Management Commentary: The disclosure is qualified in its entirety by the full text of the Press Release furnished as Exhibit 99.1. The information is being furnished and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Risks and Contingencies: The filing does not explicitly detail risks or contingencies beyond the standard regulatory process implied by the pending FDA 510(k) submission. Success of the Method Comparison Study is a prerequisite for the intended market clearance.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) for specific details on the study design, participating sites, and timeline.
- Confirm the status of the FDA 510(k) submission process and any prior interactions with the FDA regarding codeine screening.
- Review the Company's latest 10-K or 10-Q filings for financial health, as this 8-K contains no financial data.
- Monitor future filings for the results of the Method Comparison Study and the FDA's decision on the 510(k) submission.